Literature DB >> 18813901

[Radiotherapy for locally advanced prostate cancer].

K Herfarth1, F Sterzing.   

Abstract

Technical developments in radiation oncology have led to major improvements in the treatment of locally advanced prostate cancer. This article summarizes the publications on dose escalation, including the side effects. The effect of additional hormonal therapy and irradiation of the pelvic lymphatics is also discussed.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18813901     DOI： 10.1007/s00120-008-1872-5

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  30 in total

1.  Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.

Authors:  William U Shipley; J D Lu; Michael V Pilepich; Kateri Heydon; Mack Roach; Harvey B Wolkov; William T Sause; Philip Rubin; Colleen A Lawton; Mitchell Machtay
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

2.  Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation.

Authors:  D L Joon; M Hasegawa; C Sikes; V S Khoo; N H Terry; G K Zagars; M L Meistrich; A Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-15       Impact factor: 7.038

3.  A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.

Authors:  Koichiro Akakura; Hiroyoshi Suzuki; Tomohiko Ichikawa; Hiroyuki Fujimoto; Osamu Maeda; Michiyuki Usami; Daisaku Hirano; Yukie Takimoto; Toshiyuki Kamoto; Osamu Ogawa; Yoshiteru Sumiyoshi; Jun Shimazaki; Tadao Kakizoe
Journal:  Jpn J Clin Oncol       Date:  2006-11-02       Impact factor: 3.019

4.  Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.

Authors:  M J Zelefsky; D Cowen; Z Fuks; M Shike; C Burman; A Jackson; E S Venkatramen; S A Leibel
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

5.  Radical surgery versus radiotherapy for adenocarcinoma of the prostate.

Authors:  D F Paulson; G H Lin; W Hinshaw; S Stephani
Journal:  J Urol       Date:  1982-09       Impact factor: 7.450

6.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Authors:  M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

7.  Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients.

Authors:  Michael T Spiotto; Steven L Hancock; Christopher R King
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-24       Impact factor: 7.038

8.  A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy.

Authors:  Derek B Chism; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

9.  Hazards of dose escalation in prostate cancer radiotherapy.

Authors:  Deborah Kuban; Alan Pollack; Eugene Huang; Larry Levy; Lei Dong; George Starkschall; Isaac Rosen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-12-01       Impact factor: 7.038

10.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Authors:  Patrick A Kupelian; Louis Potters; Deepak Khuntia; Jay P Ciezki; Chandana A Reddy; Alwyn M Reuther; Thomas P Carlson; Eric A Klein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-01-01       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.